Literature DB >> 16339060

Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice.

Dionyssios N Sgouras1, Effrosini G Panayotopoulou, Beatriz Martinez-Gonzalez, Kalliopi Petraki, Spyros Michopoulos, Andreas Mentis.   

Abstract

In clinical settings, Lactobacillus johnsonii La1 administration has been reported to have a favorable effect on Helicobacter pylori-associated gastritis, although the mechanism remains unclear. We administered, continuously through the water supply, live La1 to H. pylori-infected C57BL/6 mice and followed colonization, the development of H. pylori-associated gastritis in the lamina propria, and the levels of proinflammatory chemokines macrophage inflammatory protein 2 (MIP-2) and keratinocyte-derived cytokine (KC) in the serum and gastric tissue over a period of 3 months. We documented a significant attenuation in both lymphocytic (P=0.038) and neutrophilic (P=0.003) inflammatory infiltration in the lamina propria as well as in the circulating levels of anti-H. pylori immunoglobulin G antibodies (P=0.003), although we did not observe a suppressive effect of La1 on H. pylori colonizing numbers. Other lactobacilli, such as L. amylovorus DCE 471 and L. acidophilus IBB 801, did not attenuate H. pylori-associated gastritis to the same extent. MIP-2 serum levels were distinctly reduced during the early stages of H. pylori infection in the La1-treated animals, as were gastric mucosal levels of MIP-2 and KC. Finally, we also observed a significant reduction (P=0.046) in H. pylori-induced interleukin-8 secretion by human adenocarcinoma AGS cells in vitro in the presence of neutralized (pH 6.8) La1 spent culture supernatants, without concomitant loss of H. pylori viability. These observations suggest that during the early infection stages, administration of La1 can attenuate H. pylori-induced gastritis in vivo, possibly by reducing proinflammatory chemotactic signals responsible for the recruitment of lymphocytes and neutrophils in the lamina propria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339060      PMCID: PMC1317072          DOI: 10.1128/CDLI.12.12.1378-1386.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  54 in total

1.  Chronic erosions of the antral mucosa: a sequela of Helicobacter pylori-induced gastritis.

Authors:  M Stolte; S Eidt
Journal:  Z Gastroenterol       Date:  1992-12       Impact factor: 2.000

2.  Molecular analysis of the lactacin F operon.

Authors:  C Fremaux; C Ahn; T R Klaenhammer
Journal:  Appl Environ Microbiol       Date:  1993-11       Impact factor: 4.792

3.  Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island.

Authors:  Jérôme Viala; Catherine Chaput; Ivo G Boneca; Ana Cardona; Stephen E Girardin; Anthony P Moran; Rafika Athman; Sylvie Mémet; Michel R Huerre; Anthony J Coyle; Peter S DiStefano; Philippe J Sansonetti; Agnès Labigne; John Bertin; Dana J Philpott; Richard L Ferrero
Journal:  Nat Immunol       Date:  2004-10-17       Impact factor: 25.606

4.  IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation.

Authors:  B Siegmund; H A Lehr; G Fantuzzi; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

5.  Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice.

Authors:  Kathene Candace Johnson-Henry; David J Mitchell; Yaron Avitzur; Esther Galindo-Mata; Nicola L Jones; Philip M Sherman
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

6.  The orphan mouse receptor interleukin (IL)-8R beta binds N51. Structure-function analysis using N51/IL-8 chimeric molecules.

Authors:  J N Heinrich; R Bravo
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

7.  Changes in the gastric mucosa following eradication of Helicobacter pylori.

Authors:  R M Genta; G M Lew; D Y Graham
Journal:  Mod Pathol       Date:  1993-05       Impact factor: 7.842

8.  NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Warren Strober
Journal:  Nat Immunol       Date:  2004-06-27       Impact factor: 25.606

9.  Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa.

Authors:  J E Crabtree; J I Wyatt; L K Trejdosiewicz; P Peichl; P H Nichols; N Ramsay; J N Primrose; I J Lindley
Journal:  J Clin Pathol       Date:  1994-01       Impact factor: 3.411

Review 10.  Macrophage inflammatory proteins: biology and role in pulmonary inflammation.

Authors:  K E Driscoll
Journal:  Exp Lung Res       Date:  1994 Nov-Dec       Impact factor: 2.459

View more
  30 in total

1.  In vitro and in vivo activities of Chios mastic gum extracts and constituents against Helicobacter pylori.

Authors:  Sotirios Paraschos; Prokopios Magiatis; Sofia Mitakou; Kalliopi Petraki; Antonios Kalliaropoulos; Petros Maragkoudakis; Andreas Mentis; Dionyssios Sgouras; Alexios-Leandros Skaltsounis
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Microbiota-Derived Metabolic Factors Reduce Campylobacteriosis in Mice.

Authors:  Xiaolun Sun; Kathryn Winglee; Raad Z Gharaibeh; Josee Gauthier; Zhen He; Prabhanshu Tripathi; Dorina Avram; Steven Bruner; Anthony Fodor; Christian Jobin
Journal:  Gastroenterology       Date:  2018-02-01       Impact factor: 22.682

3.  Effect of Porphyromonas gingivalis and Lactobacillus acidophilus on secretion of IL1B, IL6, and IL8 by gingival epithelial cells.

Authors:  Jun-jun Zhao; Xi-ping Feng; Xiu-li Zhang; Ke-yi Le
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

4.  Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori.

Authors:  Luc De Vuyst; Pascal Vincent; Eleftherios Makras; Frédéric Leroy; Bruno Pot
Journal:  Probiotics Antimicrob Proteins       Date:  2010-03       Impact factor: 4.609

5.  Use of selected lactic acid bacteria in the eradication of Helicobacter pylori infection.

Authors:  Jin-Eung Kim; Min-Soo Kim; Yeo-Sang Yoon; Myung-Jun Chung; Do-Young Yum
Journal:  J Microbiol       Date:  2014-10-03       Impact factor: 3.422

6.  Helicobacter felis--associated gastric disease in microbiota-restricted mice.

Authors:  Julia M Schmitz; Carolyn G Durham; Trenton R Schoeb; Thomas D Soltau; Kyle J Wolf; Scott M Tanner; Vance J McCracken; Robin G Lorenz
Journal:  J Histochem Cytochem       Date:  2011-09       Impact factor: 2.479

Review 7.  Probiotics for the treatment of Helicobacter pylori infection in children.

Authors:  Lucia Pacifico; John Frederick Osborn; Enea Bonci; Sara Romaggioli; Rossella Baldini; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

8.  Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4.

Authors:  Chao Zhou; Feng-Zhen Ma; Xue-Jie Deng; Hong Yuan; Hong-Sheng Ma
Journal:  World J Gastroenterol       Date:  2008-08-28       Impact factor: 5.742

9.  Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity.

Authors:  Mitsuko L Yamamoto; Irene Maier; Angeline Tilly Dang; David Berry; Jared Liu; Paul M Ruegger; Jiue-In Yang; Phillip A Soto; Laura L Presley; Ramune Reliene; Aya M Westbrook; Bo Wei; Alexander Loy; Christopher Chang; Jonathan Braun; James Borneman; Robert H Schiestl
Journal:  Cancer Res       Date:  2013-07-15       Impact factor: 12.701

Review 10.  The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis.

Authors:  Alexander Sheh; James G Fox
Journal:  Gut Microbes       Date:  2013-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.